SynthesisFrontiers in immunology2025
Prognostic value of baseline LIPI, LDH and dNLR in ES-SCLC patients receiving immune checkpoint inhibitors: a systematic review and meta-analysis.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Article
- Prognostic nomogram for extensive-stage small-cell lung cancer in the immunotherapy era: a multicenter study of first-line platinum-etoposide with or without a PD-1/PD-L1 inhibitor.Translational lung cancer research · 2026Article
- Combined Lung Immune Prognostic Index (LIPI)-Glasgow Prognostic Score (GPS) as a Prognostic Tool in Extensive-Stage Small-Cell Lung Cancer Treated with First-Line Chemo-Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Efficacy and patient selection of consolidative thoracic radiotherapy following chemoimmunotherapy in ES-SCLC.Frontiers in cell and developmental biology · 2026Article
- Prognostic impact of baseline blood biomarkers in SCLC first-line treatment.Therapeutic advances in medical oncology · 2026Article
- An LDH-based prognostic model for extensive-stage small-cell lung cancer patients treated with chemo-immunotherapy and consolidative thoracic radiotherapy.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Existing research presents conflicting findings on how baseline lung immune prognostic index (LIPI), lactate dehydrogenase (LDH), and derived neutrophil-to-lymphocyte ratio (dNLR) levels influence the prognosis of patients with extensive-stage small cell lung cancer (ES-SCLC) undergoing treatment with immune checkpoint inhibitors (ICIs). This meta-analysis aims to clarify their impact. Methods: A comprehensive search of published literature up to January 1, 2025 was conducted in PubMed, Web of Science, Cochrane Library, and Embase. The study evaluated the association between baseline LIPI, LDH, and dNLR levels and overall survival (OS) and progression-free survival (PFS) in ES-SCLC patients receiving ICIs. Subgroup analyses were performed based on relevant factors, and the study adhered to PRISMA 2020 guidelines. Results: This meta-analysis included 23 studies (LIPI: 10 studies/1,291 patients; LDH: 17 studies/1,768 patients; dNLR: 5 studies/324 patients). Elevated LIPI was significantly associated with poorer PFS (hazard ratio (HR) = 1.57, 95% confidence interval (95% CI) 1.20 - 2.06; I² = 59.0%, P = 0.013) and OS (HR = 1.76, 95% CI 1.26 - 2.45; I² = 64.2%, P < 0.001). Baseline LDH correlated with poorer OS (HR = 1.70, 95% CI 1.29 - 2.24; I² = 78.7%, P < 0.001), while elevated dNLR affected OS (HR = 2.05, 95% CI 1.02 - 4.12; I² = 86.31%, P < 0.001). Subgroup analysis showed that LIPI-PFS heterogeneity came from univariate and multivariate groupings. And LDH-OS heterogeneity was driven by country grouping. Conclusion: In ES-SCLC patients treated with ICIs, elevated baseline LIPI indicates reduced PFS and OS, while higher LDH and dNLR levels correlate with poorer OS. Monitoring these biomarkers can inform clinical decisions and enhance patient counseling. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251123579, identifier CRD420251123579.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.